The basis for drug treatment of the overactive bladder

被引:0
|
作者
K. E. Andersson
C. Chapple
A. Wein
机构
[1] Department of Clinical Pharmacology,
[2] Lund University Hospital,undefined
[3] S-221 85 Lund,undefined
[4] Sweden e-mail: Karl-Erik.Andersson@klinfarm.lu.se Tel.: +46-46-173350; Fax: +46-46-2111987,undefined
[5] Department of Urology,undefined
[6] Royal Hallamshire Hospital,undefined
[7] Sheffield,undefined
[8] UK,undefined
[9] Division of Urology,undefined
[10] University of Pennsylvania Health System,undefined
[11] Philadelphia,undefined
[12] USA,undefined
来源
World Journal of Urology | 2001年 / 19卷
关键词
Key words urinary incontinence; bladder contraction; micturition reflex; neurotransmitters; muscarinic receptors; sensory mechanisms;
D O I
暂无
中图分类号
学科分类号
摘要
 The normal bladder functions, storage and elimination of urine, are dependent on neural circuits in the brain and spinal cord that coordinate the activity of the detrusor and that of the smooth and striated muscles of the outflow region. Disturbances at different levels may cause the overactive bladder (OAB) syndrome, characterized by urge, frequency and urge incontinence. Knowledge about the mechanisms controlling both normal and abnormal micturition is mandatory for the detection of targets for pharmacological intervention. Such targets may be found in the central nervous system (CNS) or peripherally. Several CNS transmitters can modulate voiding, but few drugs with a defined CNS site of action have been demonstrated to be clinically useful. Traditionally, drugs for treatment of OAB have had a peripheral site of action. Antimuscarinics are still the gold standard, but their wellknown side effects have focused interest on other modalities of treatment. Promising preclinical results have been obtained for some principles, but so far there are few positive clinical proof of concept studies available.
引用
收藏
页码:294 / 298
页数:4
相关论文
共 50 条
  • [41] Under Treatment of Overactive Bladder
    Ballert, Katie N.
    JOURNAL OF UROLOGY, 2010, 183 (04): : 1282 - 1283
  • [42] Imidafenacin for the treatment of overactive bladder
    Maggiore, Umberto Leone Roberti
    Scala, Carolina
    Venturini, Pier Luigi
    Ferrero, Simone
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (10) : 1383 - 1397
  • [43] Diagnosis and treatment of the overactive bladder
    Wein, AJ
    UROLOGY, 2003, 62 (5B) : 20 - 27
  • [44] AbobotulinumtoxinA for the treatment of overactive bladder
    Flint, Richard
    Rantell, Angie
    Cardozo, Linda
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (10) : 1005 - 1013
  • [45] Tolterodine for treatment of overactive bladder
    Kanofsky, Jamie A.
    Nitti, Victor W.
    UROLOGIC CLINICS OF NORTH AMERICA, 2006, 33 (04) : 447 - +
  • [46] Onabotulinumtoxin A for the treatment of overactive bladder
    Cox, Lindsey
    Cameron, Anne P.
    RESEARCH AND REPORTS IN UROLOGY, 2014, 6 : 79 - 89
  • [47] DarifenacinIn the Treatment of Overactive Bladder
    Katherine F. Croom
    Gillian M. Keating
    Drugs & Aging, 2004, 21 : 885 - 892
  • [48] Darifenacin for the treatment of overactive bladder
    Haab, Francois
    WOMENS HEALTH, 2005, 1 (03) : 331 - 343
  • [49] Darifenacin in the treatment of overactive bladder
    Parsons, M
    Robinson, D
    Cardozo, L
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2005, 59 (07) : 831 - 838
  • [50] Darifenacin in the treatment of overactive bladder
    Haab, F
    DRUGS OF TODAY, 2005, 41 (07) : 441 - 452